These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry. Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949 [TBL] [Abstract][Full Text] [Related]
4. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome. Hurabielle C; Thonnart N; Ram-Wolff C; Sicard H; Bensussan A; Bagot M; Marie-Cardine A Clin Cancer Res; 2017 Jul; 23(14):3619-3627. PubMed ID: 28119365 [No Abstract] [Full Text] [Related]
5. Significance of circulating T-cell clones in Sezary syndrome. Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328 [TBL] [Abstract][Full Text] [Related]
6. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes. Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229 [TBL] [Abstract][Full Text] [Related]
7. Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients. Musette P; Michel L; Jean-Louis F; Bagot M; Bensussan A Blood; 2003 Feb; 101(3):1203. PubMed ID: 12529298 [No Abstract] [Full Text] [Related]
8. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093 [TBL] [Abstract][Full Text] [Related]
9. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199 [TBL] [Abstract][Full Text] [Related]
10. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Battistella M; Leboeuf C; Ram-Wolff C; Hurabielle C; Bonnafous C; Sicard H; Bensussan A; Bagot M; Janin A Blood; 2017 Dec; 130(26):2900-2902. PubMed ID: 29089310 [No Abstract] [Full Text] [Related]
11. A continuous T-cell line from a patient with Sézary syndrome. Kaltoft K; Bisballe S; Rasmussen HF; Thestrup-Pedersen K; Thomsen K; Sterry W Arch Dermatol Res; 1987; 279(5):293-8. PubMed ID: 3498444 [TBL] [Abstract][Full Text] [Related]
12. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570 [TBL] [Abstract][Full Text] [Related]
13. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571 [TBL] [Abstract][Full Text] [Related]
14. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. Huet D; Bagot M; Loyaux D; Capdevielle J; Conraux L; Ferrara P; Bensussan A; Marie-Cardine A J Immunol; 2006 Jan; 176(1):652-9. PubMed ID: 16365461 [TBL] [Abstract][Full Text] [Related]
15. [Epidermotropic T cell lymphomas as models for tumor progression]. Bagot M; Bensussan A Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762 [TBL] [Abstract][Full Text] [Related]
16. [Sézary syndrome. Clinical, immunological and proliferative kinetics]. Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012 [TBL] [Abstract][Full Text] [Related]
17. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients. Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411 [TBL] [Abstract][Full Text] [Related]
18. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208 [TBL] [Abstract][Full Text] [Related]
19. CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Rappl G; Abken H; Muche JM; Sterry W; Tilgen W; André S; Kaltner H; Ugurel S; Gabius HJ; Reinhold U Leukemia; 2002 May; 16(5):840-5. PubMed ID: 11986945 [TBL] [Abstract][Full Text] [Related]
20. [Sézary syndrome with null cells]. Szigeti A; Fazakas L; Fekete B; Nékám K; Láng I; Gergely P Orv Hetil; 1979 Jul; 120(30):1825-7. PubMed ID: 314085 [No Abstract] [Full Text] [Related] [Next] [New Search]